Nao Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nao Suzuki has a total of 694 co-authors. Here are the top co-authors by number of shared publications:
Seido Takae
Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan
23 shared publicationsYodo Sugishita
Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan
17 shared publications- Yodo Sugishita
Department of Frontier Medicine, Institute of Medical Science, St. Marianna University School of Medicine, Sugao 2-16-1, Miyamae-ku, Kawasaki 216-8512, Japan
14 shared publications - Seido Takae
Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan
13 shared publications Hideyuki Iwahata
Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan
10 shared publicationsYuki Horage
St. Marianna Medical University, Kanagawa, Japan
10 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessCurrent status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
The real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessThe real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions
Yoshihara M, et al. J Gynecol Oncol. 2027 ;38:e17. https://doi.org/10.3802/jgo.2027.38.e17
- 9 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Integrated host vulnerability assessment using prognostic nutritional index and psoas muscle index for predicting chemotherapy-related toxicity in ovarian cancer: a multicenter JGOG9005S cohort analysis
Objective: To evaluate associations of prechemotherapy prognostic nutritional index (PNI) and computed tomography (CT)-derived muscle measures with severe chemotherapy-related toxicity in ovarian cancer and explore their combined assessment. Methods: This multicenter retrospective cohort included 109 patients treated with platinum-taxane chemotherapy. PNI was calculated from laboratory values obtained immediately before the first chemotherapy cycle, irrespective of treatment sequence. Psoas muscle index (PMI) was measured centrally on baseline CT images. Associations with grade ≥ 3 chemotherapy-related adverse events were estimated using separate age- and stage-adjusted logistic models. Discrimination was compared among nested models in the same complete-case cohort. Cutoff-based and treatment-sequence analyses were exploratory. Results: Grade ≥ 3 toxicity occurred in 63 patients (57.8%). Higher PNI and PMI were associated with lower odds of severe toxicity (adjusted odds ratios, 0.966 per PNI unit; 95% CI, 0.935–0.994; P = 0.024; and 0.598 per cm2/m2; 0.379–0.899; P = 0.018, respectively). The combined PNI-PMI model showed numerically improved discrimination compared with individual parameters (area under the curve, 0.694). In exploratory cohort-defined groups, toxicity occurred in 36.4%, 58.3%, and 75.7% of patients with zero, one, and two vulnerability domains, respectively; the adjusted odds ratio was 2.38 per domain (95% CI, 1.41–4.20, P = 0.0018). Conclusions: Lower prechemotherapy PNI and lower baseline PMI were associated with severe chemotherapy-related toxicity. The combined model showed modest discrimination, and cohort-derived classifications require prospective external validation before clinical implementation.
- 9 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Integrated host vulnerability assessment using prognostic nutritional index and psoas muscle index for predicting chemotherapy-related toxicity in ovarian cancer: a multicenter JGOG9005S cohort analysis
Objective: To evaluate associations of prechemotherapy prognostic nutritional index (PNI) and computed tomography (CT)-derived muscle measures with severe chemotherapy-related toxicity in ovarian cancer and explore their combined assessment. Methods: This multicenter retrospective cohort included 109 patients treated with platinum-taxane chemotherapy. PNI was calculated from laboratory values obtained immediately before the first chemotherapy cycle, irrespective of treatment sequence. Psoas muscle index (PMI) was measured centrally on baseline CT images. Associations with grade ≥ 3 chemotherapy-related adverse events were estimated using separate age- and stage-adjusted logistic models. Discrimination was compared among nested models in the same complete-case cohort. Cutoff-based and treatment-sequence analyses were exploratory. Results: Grade ≥ 3 toxicity occurred in 63 patients (57.8%). Higher PNI and PMI were associated with lower odds of severe toxicity (adjusted odds ratios, 0.966 per PNI unit; 95% CI, 0.935–0.994; P = 0.024; and 0.598 per cm2/m2; 0.379–0.899; P = 0.018, respectively). The combined PNI-PMI model showed numerically improved discrimination compared with individual parameters (area under the curve, 0.694). In exploratory cohort-defined groups, toxicity occurred in 36.4%, 58.3%, and 75.7% of patients with zero, one, and two vulnerability domains, respectively; the adjusted odds ratio was 2.38 per domain (95% CI, 1.41–4.20, P = 0.0018). Conclusions: Lower prechemotherapy PNI and lower baseline PMI were associated with severe chemotherapy-related toxicity. The combined model showed modest discrimination, and cohort-derived classifications require prospective external validation before clinical implementation.
- 29 September 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- p. 1-7
Nationwide survey of cryostorage tank management for fertility preservation in Japan
- 29 September 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- p. 1-7
Nationwide survey of cryostorage tank management for fertility preservation in Japan
- 11 July 2026
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 115 (2) , 406-408
Tau expression and phosphorylation in rat ovary: gonadotropin-dependent regulation during oocyte maturation and degeneration
- 11 July 2026
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 115 (2) , 406-408
Tau expression and phosphorylation in rat ovary: gonadotropin-dependent regulation during oocyte maturation and degeneration
- 13 June 2026
- Published by Springer Nature
- p. 169-174
Fertility Management
- Open Access
- 1 January 2026
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 25 (1)
Institutional Perspectives on Assisted Reproductive Technology Using Third‐Party Gametes in Japan: A Nationwide Survey of Assisted Reproductive Technology Facilities
Objective: To clarify institutional perspectives on assisted reproductive technology (ART) using third‐party gametes. Methods: We surveyed 634 facilities registered with the Japan Society of Obstetrics and Gynecology, and 416 responses were included in a descriptive analysis. Results: Psychosocial and economic stability of ART recipient couples were considered necessary in most facilities (94.6%). Japanese nationality and legal marriage were necessary recipient criteria in 36.8% and 54.3% facilities, respectively. Lower and upper age limits for female recipients were 20–25 and 43–45 years, respectively, whereas most male partners had no upper age limit (34.6%–36.6%). The most common upper age limit for oocyte donors was 35 years (67.9%). In contrast, upper age limits for sperm donors were more dispersed, with 40 years being the most common age at response to intrauterine insemination (35.6%) and in vitro fertilization (35.9%). The most accepted indications were hypergonadotropic hypogonadism for oocyte donation (87.5%) and failure to retrieve sperm via micro‐testicular sperm extraction for donor sperm treatment (97.3%). Most facilities considered psychosocial support necessary. Conclusions: This study provides a comprehensive overview of institutional perspectives on third‐party ART in Japan. Although facilities showed substantial agreement on core principles, their views on specific eligibility and operational criteria varied.
- 1 January 2026
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 25 (1)
Open AccessInstitutional Perspectives on Assisted Reproductive Technology Using Third‐Party Gametes in Japan: A Nationwide Survey of Assisted Reproductive Technology Facilities
Objective: To clarify institutional perspectives on assisted reproductive technology (ART) using third‐party gametes. Methods: We surveyed 634 facilities registered with the Japan Society of Obstetrics and Gynecology, and 416 responses were included in a descriptive analysis. Results: Psychosocial and economic stability of ART recipient couples were considered necessary in most facilities (94.6%). Japanese nationality and legal marriage were necessary recipient criteria in 36.8% and 54.3% facilities, respectively. Lower and upper age limits for female recipients were 20–25 and 43–45 years, respectively, whereas most male partners had no upper age limit (34.6%–36.6%). The most common upper age limit for oocyte donors was 35 years (67.9%). In contrast, upper age limits for sperm donors were more dispersed, with 40 years being the most common age at response to intrauterine insemination (35.6%) and in vitro fertilization (35.9%). The most accepted indications were hypergonadotropic hypogonadism for oocyte donation (87.5%) and failure to retrieve sperm via micro‐testicular sperm extraction for donor sperm treatment (97.3%). Most facilities considered psychosocial support necessary. Conclusions: This study provides a comprehensive overview of institutional perspectives on third‐party ART in Japan. Although facilities showed substantial agreement on core principles, their views on specific eligibility and operational criteria varied.
- Open Access
A Comparative Analysis of Gremlin-1 (GREM1), Hyaluronic Acid Synthetase-2 (HAS2), and Prostaglandin-Endoperoxide Synthase-2 (PTGS2) Expression in Cumulus Cells Among Women with Diminished Ovarian Reserve Following Rescue In Vitro Maturation (r-IVM)
Managing women with diminished ovarian reserve for in vitro fertilization (IVF) is challenging, often resulting in low oocyte yield and cycle failures. We hypothesize that coupling in vitro fertilization (IVF) with rescue in vitro maturation (r-IVM) can improve overall maturation rates without compromising the overall IVF outcome. Our study compared DOR and normal ovarian reserve (NOR) cohorts by evaluating 15 immature oocyte progressions following r-IVM. We analyzed the gene expression of cumulus cells related to GREM1, PTGS2, and HAS2 to correlate with OQ, EQ, and overall IVF outcome. Significant differences were noted in AMH levels, AFCs, and oocyte numbers (p < 0.05). Following r-IVM, the DOR cohort achieved a 50% maturation rate with improved overall quality; however, the difference was not statistically significant (p > 0.05). Fertilization rates were comparable, but EQ was better in DOR. All genes in DOR were upregulated post-r-IVM, whereas NOR showed downregulation of PTGS2 and GREM1 (p < 0.05). Otherwise, DOR exhibited higher pregnancy rates and live birth rates, although the difference was not statistically significant (p > 0.05). Overall, our findings suggest that r-IVM could provide improved fertility outcomes for DOR women in standard IVF cycles.
Open AccessA Comparative Analysis of Gremlin-1 (GREM1), Hyaluronic Acid Synthetase-2 (HAS2), and Prostaglandin-Endoperoxide Synthase-2 (PTGS2) Expression in Cumulus Cells Among Women with Diminished Ovarian Reserve Following Rescue In Vitro Maturation (r-IVM)
Managing women with diminished ovarian reserve for in vitro fertilization (IVF) is challenging, often resulting in low oocyte yield and cycle failures. We hypothesize that coupling in vitro fertilization (IVF) with rescue in vitro maturation (r-IVM) can improve overall maturation rates without compromising the overall IVF outcome. Our study compared DOR and normal ovarian reserve (NOR) cohorts by evaluating 15 immature oocyte progressions following r-IVM. We analyzed the gene expression of cumulus cells related to GREM1, PTGS2, and HAS2 to correlate with OQ, EQ, and overall IVF outcome. Significant differences were noted in AMH levels, AFCs, and oocyte numbers (p < 0.05). Following r-IVM, the DOR cohort achieved a 50% maturation rate with improved overall quality; however, the difference was not statistically significant (p > 0.05). Fertilization rates were comparable, but EQ was better in DOR. All genes in DOR were upregulated post-r-IVM, whereas NOR showed downregulation of PTGS2 and GREM1 (p < 0.05). Otherwise, DOR exhibited higher pregnancy rates and live birth rates, although the difference was not statistically significant (p > 0.05). Overall, our findings suggest that r-IVM could provide improved fertility outcomes for DOR women in standard IVF cycles.